玻璃体切除术与阿柏西普治疗糖尿病视网膜病变玻璃体出血的视觉 acuity 及其他眼部结局:随机临床试验二次分析
该事后分析基于一项随机临床试验,纳入205只因增殖性糖尿病视网膜病变(PDR)相关玻璃体出血导致视力下降且考虑行玻璃体切除术的患眼,比较初始阿柏西普注射与玻璃体切除联合全视网膜光凝(PRP)的探索性结局。
要点
- 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。
- 全队列中玻璃体切除组玻璃体出血清除中位时间4周,显著快于阿柏西普组的36周。
- 每组约三分之一患眼在随访中接受了替代治疗,可能影响治疗决策。
核心结论
- 初始阿柏西普与玻璃体切除联合PRP均为PDR相关玻璃体出血的可行治疗方案。
- 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。
研究设计与样本
- 该研究为随机临床试验的事后分析,纳入205只因PDR相关玻璃体出血导致视力下降且考虑行玻璃体切除术的患眼。
- 受试者随机接受每月4次阿柏西普注射或玻璃体切除联合PRP,两组均可依据方案标准在随访中接受替代治疗。
主要发现
- 基线视力20/32至20/160的89只患眼中,阿柏西普组与玻璃体切除组24周视力字母评分调整平均差异为-4.3(95%CI -10.6至1.9)。
关键数值与推荐
- 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。
- 玻璃体切除联合PRP的玻璃体出血清除速度显著快于初始阿柏西普注射。
临床怎么用
- 对于PDR相关玻璃体出血,初始阿柏西普与玻璃体切除联合PRP均可选择。
- 基线视力差于20/800的患眼,可考虑初始玻璃体切除联合PRP以加快视力恢复和出血清除。
- 治疗决策需考虑约三分之一患眼在随访中接受替代治疗的可能性。
局限性
- 该研究为事后分析,探索性结局需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic retinopathy (PDR), post hoc analyses may influence treatment choices. OBJECTIVE: To compare exploratory outcomes between treatment groups that may affect treatment choices for patients with vitreous hemorrhage due to PDR. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial conducted at 39 DRCR Retina Network sites included adults with vision loss due to PDR-related vitreous hemorrhage for whom vitrectomy was considered. Data were collected from November 2016 to January 2020. INTERVENTIONS: Random assignment to 4 monthly injections of aflibercept vs vitrectomy with PRP. Both groups could receive aflibercept or vitrectomy during follow-up based on protocol-specific criteria. MAIN OUTCOMES AND MEASURES: Visual acuity area under the curve (adjusted for baseline VA) and clearance of vitreous hemorrhage. RESULTS: A total of 205 eyes were included in the analysis (115 male [56%] and 90 [44%] female participants; mean [SD] age, 57 [11] years). Among 89 eyes with a baseline VA of 20/32 to 20/160 (47 receiving aflibercept, including 4 [9%] that had undergone vitrectomy; 42 undergoing vitrectomy, including 3 [7%] that had received aflibercept), the adjusted mean difference in VA letter score over 24 weeks between the aflibercept and vitrectomy groups was -4.3 (95% CI, -10.6 to 1.9) compared with -16.7 (95% CI, -24.4 to -9.1) among 59 eyes with baseline VA worse than 20/800 (P = .02 for interaction; 26 in the aflibercept group, including 6 [23%] that had undergone vitrectomy; 33 in the vitrectomy group, including 8 [24%] that had received aflibercept). In the full cohort, the median time to clearance of the initial vitreous hemorrhage was 36 (interquartile range [IQR], 24-52) weeks in the aflibercept group vs 4 (IQR, 4-4) weeks in the vitrectomy group (difference, 32 [95% CI, 20-32] weeks; P < .001). CONCLUSIONS AND RELEVANCE: Both initial aflibercept and vitrectomy with PRP are viable treatment approaches for PDR-related vitreous hemorrhage. Although this study did not find a significant difference between groups in the primary outcome of mean VA over 24 weeks of follow-up, eyes receiving initial vitrectomy with PRP had faster recovery of vision over 24 weeks when baseline VA was worse than 20/800 and faster vitreous hemorrhage clearance. Approximately one-third of the eyes in each group received the alternative treatment (aflibercept or vitrectomy with PRP). These factors may influence treatment decisions for patients initiating therapy for PDR-related vitreous hemorrhage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02858076.
引用
- Glassman AR, Beaulieu WT, Maguire MG, et al. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33956075. doi:10.1001/jamaophthalmol.2021.1110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。